GLP-1 Receptor Agonists

Clinical Research & Data

GLP-1 receptor agonists represent one of the most significant advancements in metabolic medicine. Below is a comprehensive summary of pivotal clinical trials and real-world data for established and emerging therapies in this class.

Evidence-Based

Data from peer-reviewed clinical trials

Transparent

Objective analysis of published results

Educational

Research for informational and educational purposes

Established GLP-1 Therapies

TIRZEPATIDE

(Mounjaro® / Zepbound®)

Dual GIP and GLP-1 receptor agonist

Trial	Duration	Population	Avg Weight Loss	Key Outcomes
SURMOUNT-1	72 weeks	Obesity or overweight without diabetes	5 mg: 16.0% 10 mg: 21.4% 15 mg: 22.5%	•Up to 57% achieved ≥20% weight loss •91% achieved ≥5% weight loss (15 mg) •Significant improvements in waist circumference, BP, and metabolic markers
SURMOUNT-4 (Long-term)	88 weeks	Obesity or overweight without diabetes	25.3% (15 mg)	•Sustained weight loss with continued treatment •Improvements in cardiometabolic risk factors

Sources: Jastreboff AM, et al. N Engl J Med. 2022;387:205-216. | Jastreboff AM, et al. N Engl J Med. 2023;388:514-526.

SEMAGLUTIDE

(Ozempic® / Wegovy®)

GLP-1 receptor agonist

Trial	Duration	Population	Avg Weight Loss	Key Outcomes
STEP-1	68 weeks	Obesity or overweight without diabetes	14.9%	•86% achieved ≥5% weight loss •~40% achieved ≥20% weight loss •Improvements in cardiometabolic risk factors
STEP-5 (Long-term)	104 weeks	Obesity or overweight without diabetes	15.0%	•Weight loss maintained through 104 weeks •Sustained improvements in cardiometabolic health

Sources: Wilding JPH, et al. N Engl J Med. 2021;384:989-1002. | Rubino D, et al. Diabetes Care. 2022;45:2272-2281.

Emerging & Next-Generation GLP-1 Therapies

RETATRUTIDE

(TRIUMPH-1)

Triple GIP, GLP-1, and Glucagon Receptor Agonist

Trial	Duration	Population	Avg Weight Loss	Key Outcomes
TRIUMPH-1	80–104 weeks	Obesity or overweight without diabetes	28.3% (80 weeks) 30.3% (104 weeks) 45.3% achieved >30% weight loss	•Highest weight loss observed among clinical-stage therapies •Significant improvements in metabolic markers and body composition

Sources: Rosenstock J, et al. Lancet. 2023;402:529-539.

CAGRI-SEMAGLUTIDE

(REDEFINE-1)

Combination: Semaglutide + Cagrilintide

Trial	Duration	Population	Avg Weight Loss	Key Outcomes
REDEFINE-1	68 weeks	Obesity or overweight without diabetes	15.7%	•Superior weight loss vs semaglutide alone •Greater improvements in metabolic markers and body composition

Sources: Frias JP, et al. Lancet. 2023;401:563-575.

MAZUTIDE

(Phase 2)

GLP-1 / Glucagon Dual Agonist

Trial	Duration	Population	Avg Weight Loss	Key Outcomes
Phase 2 Trial	48–68 weeks	Obesity or overweight without diabetes	Up to 17% (~14% average)	•Dose-dependent weight loss •Well tolerated across dose ranges

Sources: ClinicalTrials.gov Identifier: NCT05003146.

Important Information

The data presented above is for informational and educational purposes only. Nexogen Research does not provide medical advice. Always consult a qualified healthcare professional before making any medical decisions.